Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Stem Cell Targeting Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LGR5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGR5 ECD-Fc Fusion Protein HEK293 Expressed, High Purity (>95%), Endotoxin <1EU/μg, Sequence Verified by Mass Spec. |
View LGR5 Products |
| Gene Delivery | LGR5 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Suitable for Flow Cytometry and Calcium Flux assays. |
View LGR5 Products |
| Benchmark Ab | Anti-LGR5 Reference Antibody Recombinant positive control for binding and internalization assays. |
View LGR5 Products |
| Validator | LGR5 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View LGR5 Products |
| Related Target: LGR4 | LGR4 Protein / Lentivirus Subfamily off-target screening. High homology requires strict selectivity assays. |
View LGR4 Products |
| Related Target: LGR6 | LGR6 Protein / Lentivirus Paralog specificity control for pan-LGR screening. |
View LGR6 Products |
| Related Target: RSPO1 | RSPO1 Recombinant Protein LGR5 ligand for competitive binding and Wnt signaling assays. |
View RSPO1 Products |
| Related Target: RNF43 | RNF43 E3 ubiquitin-protein ligase interacting with Wnt signaling complex. For mechanism and combination studies. |
View RNF43 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (LGR4/LGR5/LGR6 Cross-reactivity) | Human/Mouse/Cyno Ortholog Panel for LGR4, LGR5, LGR6. All >95% purity, Sequence Verified, endotoxin-controlled for sensitive stem cell assays. |
| Native Conformation for Binding & Calcium Flux | Full-length LGR5 Lentivirus for stable cell line generation. Preserves 7-TM domain structure and native glycosylation pattern. |
| ADC Internalization Efficiency | High-purity LGR5 ECD-Fc with verified R-spondin binding site accessibility. Suitable for confocal internalization and pH-sensitive dye assays. |
| Lack of Functional Controls | Validated siRNA sets and benchmark antibodies included for assay standardization. |
Live LGR5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGR5-targeted therapeutics centers on eradicating Cancer Stem Cells (CSCs) responsible for relapse and metastasis. As first-generation ADCs enter Phase I/II trials, the critical challenge remains therapeutic index—distinguishing malignant CSCs from normal intestinal crypt base columnar cells. The next wave of R&D focuses on bispecific modalities that redirect immune cells specifically to LGR5+ tumors while sparing normal stem cell niches, and combination strategies with Wnt pathway inhibitors to overcome compensatory signaling.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | BMS (Celgene), Roche, Bionomics, Merus | Colorectal Cancer, Gastric Cancer | Internalization & pH-Dependent Release Assays. Need high-purity ECD-Fc for FACS-based internalization quantification. |
| Bispecific T-cell Engager | Merus, Biotech Ventures, Academic Labs | Solid Tumors (CSC-targeted) | Cross-reactivity Screening vs LGR4/LGR6. Requires homolog panel proteins to ensure CSC-specificity. |
| CAR-T Cell Therapy | Cell Therapy Companies | Refractory Solid Tumors | Cell-based Binding Assays using Lentivirus-expressing Full-length LGR5 to verify CAR specificity. |